Caris Life Sciences, Inc. CAI
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 2,494.03% | -24.90% | -100.62% | 236.92% | 133.88% |
| Total Depreciation and Amortization | 1.04% | 29.08% | 18.04% | -11.89% | -24.01% |
| Total Amortization of Deferred Charges | 4.01% | -88.61% | 333.72% | -75.44% | -68.24% |
| Total Other Non-Cash Items | -52.40% | 179.45% | 2.27% | 2.06% | -74.86% |
| Change in Net Operating Assets | -156.22% | -418.19% | 114.02% | -519.51% | 1,078.94% |
| Cash from Operations | -178.12% | -13.38% | -26.58% | -28.27% | 756.55% |
| Capital Expenditure | 20.86% | -113.45% | -103.18% | 28.26% | -411.90% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Investing | 85.70% | -1,081.51% | -103.18% | 28.26% | -411.90% |
| Total Debt Issued | -100.00% | -- | -- | -- | -100.00% |
| Total Debt Repaid | 99.99% | -1,015,772.50% | -2.56% | -69.57% | -4.55% |
| Issuance of Common Stock | 563.21% | 299.78% | -76.18% | 235.53% | -99.78% |
| Repurchase of Common Stock | 62.01% | -47,444.64% | 86.79% | 97.44% | -898.79% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | 100.00% | -230.83% |
| Cash from Financing | 138.57% | -4,578.52% | -75.76% | 116.11% | -103.10% |
| Foreign Exchange rate Adjustments | -314.81% | -170.00% | 65.52% | -146.77% | -33.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 80.41% | -659.56% | -45.78% | 25.56% | -95.01% |